novo nordisk semaglutide clinical trials said on Tuesday its triple agonist UBT251 of the receptors for GLP-1, GIP and glucagon, jointly developed with United Biotechnology, achieved a statistically significant mean weight loss of up to PDF file of registered information

M., Abela, S., Quteishat, B., et al

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet, 2023

Upon stopping, users may experience: Regular monitoring is essential to prevent complications, especially in diabetic patients at risk for cardiovascular disease

Physiological adaptations to weight loss and factors favouring weight regain

For individuals with diabetes and overweight or obesity, the ADA recommends as preferred pharmacotherapy a GLP-1 receptor agonist or a dual GLP-1/GIP receptor agonist with substantial weight-loss efficacy, meaning semaglutide or tirzepatide

Retrieved May 6, 2025, from Biom Probiotics